(1) OBNM APPROVED KETAMINE COURSES FOR 850-060-0210
- OBNM approved courses on Ketamine and Psychedelic Therapies click here
- As a reminder – any courses approved by the following are preapproved by OBNM and may be submitted for compliance with the rule.
· Accreditation Council for Continuing Medical Education (ACCME)
· American Council on Pharmaceutical Education (ACPE)
- The following links are provided as an FYI – the Board has not approved all courses provided by the following, and are not endorsing / promoting any of the following providers. This list is a resource for CE on Ketamine and Psychedelic Therapies.
IMPORTANT NOTE: NDs must apply for Board approval prior to taking a course that has not been approved by OBNM, ACCME, ACPE. CE application for Licensees: https://www.oregon.gov/obnm/Documents/CE/CEApplication2017.pdf
(2) IMPORTANT UPDATE TO APPROVAL PROCESS / TIME LINE FOR COMPLIANCE – based on Licensee feedback, please see the following accommodations for compliance.
- Submission / Applications for Approval Required by Dec. 31, 2022: Licensees who prescribe non-topical ketamine – meaning all forms / purposes other than those excluded from the rule, must either submit certificates of completion of prior education, confirmation of registration for a pre-approved course per above, or submit an application to the Board for approval of continuing education as required by the rule by December 31, 2022 . CE application for Licensees: https://www.oregon.gov/obnm/Documents/CE/CEApplication2017.pdf
- Continuation of Practice: Licensees who submit either certificates of completion, confirmation of registration for a pre-approved course, or a CE application for Board approval for an upcoming course(s) by Dec. 31, 2022, may continue to prescribe Ketamine pending Board approval of their submission and completion of the course. Any courses taken after January 1, 2023 may be applied to your annual renewal for 2023-2024.
- REMINDER: The Board will accept continuing education certificates of completion for courses approved and earned prior to January 1,2023. YOU DO NOT NEED TO RE-TAKE COURSES IF YOU ALREADY COMPLETED THE REQUIRED COURSES SET FORTH IN THE RULE!
Please send your submission to the Board by Dec. 31, 2022 via email email@example.com
(3). APPLICATION OF THE RULE: The training and education required in this rule only applies to licensees who prescribe ketamine as stated in the rule.
850-060-0210 Education and Reporting Requirements for Ketamine Therapy
- Prior to prescribing non-topical ketamine; a Licensee must provide the Board proof of completion of four (4) hours of Board approved pharmacology education on prescribing Ketamine, including dosage and administration, clinical indications, and safety planning
- Prior to prescribing non-topical ketamine, unless prescribing ketamine for pain management only, a Licensee must provide the Board proof of completion of two (2) hours of Board approved ethics education on Ketamine prescribing and treatment, including doctor-patient boundaries, enhanced consent, and therapy models.
- IV and Injectable Ketamine must be administered and supervised for the duration of the treatment by a Licensee who has completed the required training in Section 1 and 2.
- Licensees may submit to the Board proof of approved education required in Section 1 and 2, earned before December 31, 2022, for approval for compliance with this rule.
Beginning January 1, 2023, injectable ketamine is not excluded from the naturopathic formulary and is in scope for naturopathic providers who have completed be required education per 850-060-0210.
850-060-0223 Formulary Compendium Exclusions (in relevant part)
The Formulary Council has approved substances as listed by classification in 850-060-0226 for use by Naturopathic physicians in accordance with professional standards of care.
(1) This authority does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents or any other education and training required to prescribe, dispense, administer, or order all legend or controlled substances.
(2) Additionally, the following substances may not be prescribed by licensees of this Board.
(a) General anesthetics
(b) Injectable Ketamine for the purpose of general anesthesia
(c) Mifepristone and Misoprostol as an abortifacient
(d) Buprenorphine in any formulation for diagnosis for opioid use disorder
(e) Barbiturates; with the exception of the following: